Theranostics 2011; 1:211-219. doi:10.7150/thno/v01p0211 This volume
Integrin Targeted Delivery of Gene Therapeutics
Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
Juliano RL, Ming X, Nakagawa O, Xu R, Yoo H. Integrin Targeted Delivery of Gene Therapeutics. Theranostics 2011; 1:211-219. doi:10.7150/thno/v01p0211. Available from https://www.thno.org/v01p0211.htm
Integrins have become key targets for molecular imaging and for selective delivery of anti-cancer agents. Here we review recent work concerning the targeted delivery of antisense and siRNA oligonucleotides via integrins. A variety of approaches have been used to link oligonucleotides to ligands capable of binding integrins with high specificity and affinity. This includes direct chemical conjugation, incorporating oligonucleotides into lipoplexes, and use of various polymeric nanocarriers including dendrimers. The ligand-oligonucleotide conjugate or complex associates selectively with the integrin, followed by internalization into endosomes and trafficking through subcellular compartments. Escape of antisense or siRNA from the endosome to the cytosol and nucleus may come about through endogenous trafficking mechanisms, or because of membrane disrupting capabilities built into the conjugate or complex. Thus a variety of useful strategies are available for using integrins to enhance the pharmacological efficacy of therapeutic oligonucleotides.
Keywords: Gene therapy, Integrin, RGD peptides, Antisense and siRNA oligonucleotides, Endosome escape.